Background/Aims: The observed prevalence of hemochromatosis has ranged
considerably from 0.05 to 0.37% in studies requiring liver biopsy. We
aimed to study the prevalence of genetic hemochromatosis among Norweg
ian blood donors. Methods: We studied 10552 healthy blood donors (5312
women and 5240 men) using serum ferritin as a screening parameter. If
serum ferritin concentration was greater than or equal to 100 mu g/l
in women and greater than or equal to 200 mu g/l in men, serum iron an
d transferrin (measured as total iron binding capacity = TIBC) were me
asured, Blood donors who repeatedly had a transferrin saturation above
40% and a ferritin concentration above these limits were referred to
a hepatologist (H.B.). Results: Serum ferritin was greater than or equ
al to 100 mu g/l in 94/5312 (1.8%) women and greater than or equal to
200 mu l in 79/5240 (1.5%) men. Of these, 37 persons had a serum ferri
tin concentration above 100 mu g/l (females) or above 200 mu g/l (male
s) and a transferrin saturation above 40%. Nineteen of them (13 men an
d 6 women, median age 36 years, range 28-68) were identified as having
hemochromatosis on the basis of increased hepatic iron index, Serum f
erritin ranged from 111 to 1980 mu g/l (median 357 mu g/l and transfer
rin saturation from 50 to 100% (median 92%), hepatic iron from 48 to 4
71 mu mol/g dry weight (median 118 mu mol/g) and hepatic iron index fr
om 1.5 to 12.1 (median 3.0), One person had cirrhosis and none had dia
betes, The prevalence of hemochromatosis was significantly higher amon
g first-time blood donors (12 out of 3500 [3.4/1000]) compared with re
peat donors (7 out of 7052 [1/1000]), p < 0.005. Conclusions: The obse
rved prevalence of hemochromatosis in Norwegian first-time blood donor
s of 0.34% is comparable to recently observed prevalences in other stu
dies, However, the use of serum ferritin as a first-step screening too
l may have failed to detect hemochromatosis in the early stage where i
ron overload has not yet occurred.